Maze Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Maze Therapeutics Inc. | MAZE - NASDAQ |
$15.00-$17.00 | $16.00 | $16.12 | 8.75 million | 1/31/2025 |
| J.P. Morgan, TD Cowen, Leerink Partners, Guggenheim Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Terms Added 2025-01-27 | ||||||
Maze Therapeutics Inc. Quote & Chart - Click for current quote - MAZE
IPO Boutique aggregates information on public companies and private companies, such as "MAZE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Maze Therapeutics Inc. (adapted from Maze Therapeutics Inc. prospectus):
They are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MAZE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.